Patents by Inventor Sara Blumenstein

Sara Blumenstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FGF-2 VARIANTS HAVING N-TERMINAL DELETIONS AND INCREASED RECEPTOR SELECTIVITY AND USES THEREOF
    Publication number: 20180127475
    Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides comprising a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions comprising same and methods for use thereof.
    Type: Application
    Filed: December 12, 2017
    Publication date: May 10, 2018
    Applicants: PROCHON BIOTECH LTD., HEPACORE LTD.
    Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
  • FGF-2 variants having N-terminal deletions and increased receptor selectivity and methods of use thereof
    Patent number: 9862753
    Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 polypeptides comprising a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions comprising same and methods for use thereof.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: January 9, 2018
    Assignees: PROCHON BIOTECH LTD., HEPACORE LTD
    Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
  • FGF-2 VARIANTS HAVING N-TERMINAL DELETIONS AND INCREASED RECEPTOR SELECTIVITY AND USES THEREOF
    Publication number: 20150322126
    Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides comprising a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions comprising same and methods for use thereof.
    Type: Application
    Filed: February 23, 2015
    Publication date: November 12, 2015
    Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
  • FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof
    Patent number: 8962556
    Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides that include a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions of the same and methods for use thereof.
    Type: Grant
    Filed: October 7, 2007
    Date of Patent: February 24, 2015
    Assignee: Prochon Biotech Ltd.
    Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
  • METHODS AND KITS FOR DETERMINING A RISK TO DEVELOP CANCER, FOR EVALUATING AN EFFECTIVENESS AND DOSAGE OF CANCER THERAPY AND FOR CORRELATING BETWEEN AN ACTIVITY OF A DNA REPAIR ENZYME AND A CANCER
    Publication number: 20110294134
    Abstract: Methods and kits for (i) determining a risk of a subject to develop cancer; (ii) evaluating an effectiveness and dosage of cancer therapy administered to a cancer patient; and (iii) determining a presence of correlation or non-correlation between an activity of at least one DNA repair enzyme and at least one cancer, are disclosed.
    Type: Application
    Filed: August 8, 2011
    Publication date: December 1, 2011
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.
    Inventors: ZVI LIVNEH, TAMAR PAZ-ELIZUR, SARA BLUMENSTEIN
  • Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer
    Patent number: 8043807
    Abstract: Methods and kits for (i) determining a risk of a subject to develop cancer; (ii) evaluating an effectiveness and dosage of cancer therapy administered to a cancer patient; and (iii) determining a presence of correlation or non-correlation between an activity of at least one DNA repair enzyme and at least one cancer, are disclosed.
    Type: Grant
    Filed: March 21, 2002
    Date of Patent: October 25, 2011
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Zvi Livneh, Tamar Paz-Elizur, Sara Blumenstein
  • N-TERMINAL FGF VARIANTS HAVING INCREASED RECEPTOR SELECTIVITY AND USES THEREOF
    Publication number: 20110053841
    Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides that include a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions of the same and methods for use thereof.
    Type: Application
    Filed: October 7, 2007
    Publication date: March 3, 2011
    Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
  • Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer
    Publication number: 20040096863
    Abstract: Methods and kits for (i) determining a risk of a subject to develop cancer; (ii) evaluating an effectiveness and dosage of cancer therapy administered to a cancer patient; and (iii) determining a presence of correlation or non-correlation between an activity of at least one DNA repair enzyme and at least one cancer, are disclosed.
    Type: Application
    Filed: September 16, 2003
    Publication date: May 20, 2004
    Inventors: Zvi Livneh, Tamar Paz-Elizur, Sara Blumenstein
  • Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer
    Publication number: 20030003454
    Abstract: Methods and kits for (i) determining a risk of a subject to develop cancer; (ii) evaluating an effectiveness and dosage of cancer therapy administered to a cancer patient; and (iii) determining a presence of correlation or non-correlation between an activity of at least one DNA repair enzyme and at least one cancer, are disclosed.
    Type: Application
    Filed: March 23, 2001
    Publication date: January 2, 2003
    Applicant: Yeda Research and Development Co. Ltd. at The Weizmann Institute of Science
    Inventors: Zvi Livneh, Tamar Paz-Elizur, Sara Blumenstein